Recent News

• 11.03.2026 - Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
• 11.02.2026 - Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
• 10.29.2026 - Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
• 10.22.2026 - Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
• 10.20.2026 - Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
• 10.19.2026 - Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
• 10.08.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 10.07.2026 - Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
• 10.01.2026 - Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
• 09.30.2026 - Oculis Announces Resignation of Lionel Carnot from Board of Directors

Recent Filings

• 09.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2026 - EX-99.1 EX-99.1
• 08.10.2026 - EX-99.1 EX-99.1
• 08.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.06.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.25.2026 - EX-99.1 EX-99.1
• 06.01.2026 - EX-99.1 EX-99.1